Third Point’s Alexion Pharmaceuticals ALXN Stock Holding History

Third Point’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,000,000	Closed	-$140M	–	50
2017 Q3	$140M	Sell	1,000,000 -250,000	-20%	-$34M	1.18%	28
2017 Q2	$152M	Buy	+1,250,000	New	+$145M	1.35%	24

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Third Point's ALXN Position: Q4 2017 in Review

Third Point sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 1,000,000 shares — an estimated $140M sold.

Third Point first reported a position in ALXN in Q2 2017 and held it in 2 quarters. The position peaked at $152M in Q2 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

Third Point reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Third Point sold 1,000,000 Alexion Pharmaceuticals shares in Q4 2017, an estimated $140M.
Third Point first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 2 quarters.
Third Point's Alexion Pharmaceuticals position peaked at $152M in Q2 2017.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Third Point's 13F filing for Q4 2017, filed 14 Feb 2018.